Abstract 4007: Dynamics Of Platelet Chemokines In Acute Coronary Syndrome
Background: The chemokines platelet factor 4 (CXCL4) and RANTES (CCL5) are released after platelet activation. Lately, the fundamental role of platelet chemokines in the pathogenesis of atherosclerosis has emerged. Platelet activation markers are elevated in patients with coronary artery disease (CAD) and acute coronary syndrome (ACS). The protective role of aspirin in CAD may not only result from preventing acute arterial thrombosis but may have beneficial effects on the progression of atherosclerosis by stabilizing platelets.
Objective: The aim of this study was to investigate whether ACS is associated with elevated plasma concentrations of platelet chemokines and their dynamics after treatment with aspirin.
Methods: Patients presenting in the emergency ward with ACS were included. Plasma concentrations of CXCL4 and CCL5 were analysed by ELISA in a total of 145 patients (66 with ACS and 79 controls with angiographic exclusion of CAD) at admission and six hours later. Statistical analyses were performed with Kruskal-Wallis and Wilcoxon signed rank test.
Results: CXCL4 and CCL5 were significantly elevated in patients with ACS compared to patients without CAD (p<0,001). The application of the platelet aggregation inhibitor aspirin resulted in a significant decrease of RANTES after 6 hours (p<0,05) but not in patients that did not receive aspirin.
Conclusions: Platelet chemokines are elevated in patients with ACS. The decrease of the plasma concentration within a few hours after tratment with aspirin reflects reduced platelet activation and may be useful to detect aspirin resistance.